Product Description
Dornase alfa is used to reduce the number of lung infections and to improve lung function in patients with cystic fibrosis. It breaks down the thick secretions in the airways, allowing air to flow better and preventing bacteria from building up. (Sourced from: https://medlineplus.gov/druginfo/meds/a694002.html)
Mechanisms of Action: Dnase Agonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Inhalant
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Latvia | Lebanon | Lithuania | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Turkey | Ukraine | United Kingdom | United States | Uruguay
Approved Indications: Cystic Fibrosis | Pulmonary Fibrosis
Known Adverse Events: Chest Pain | Pain Unspecified | Pharyngitis | Conjunctivitis | Laryngitis | Rhinitis | Dyspnea
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|